MedPath

Topline Results from Phase 2b Clinical Trial of UBX1325 for DME Expected in Q1 2025

The phase 2b clinical trial (ASPIRE) for UBX1325, targeting diabetic macular edema (DME), is currently underway, with topline results anticipated in the first quarter of 2025.

The phase 2b study, known as ASPIRE, is currently in progress, focusing on the efficacy and safety of UBX1325 for the treatment of diabetic macular edema (DME). This clinical trial is a significant step forward in the development of new therapies for DME, a condition that affects a substantial number of individuals worldwide. The topline results from this study are eagerly awaited and are expected to be released in the first quarter of 2025. These results will provide valuable insights into the potential of UBX1325 as a treatment option for patients suffering from DME, marking a critical milestone in the ongoing efforts to address this challenging eye condition.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Autobahn Therapeutics Initiates Phase 2 Trial of ABX-002 for Bipolar Depression

Autobahn Therapeutics has begun a Phase 2 clinical trial of ABX-002 as an adjunctive treatment for bipolar depression, aiming for biological and clinical proof-of-concept.
The trial will assess changes in brain energy metabolism and depressive symptoms using neuroimaging and clinical scales, with topline data expected in H2 2025.

Cogent Biosciences' Bezuclastinib Shows Promise in Systemic Mastocytosis Trials

Cogent Biosciences reports that bezuclastinib shows a 56% average improvement in Total Symptom Score (TSS) at 24 weeks in non-advanced systemic mastocytosis (NonAdvSM) patients.
In advanced systemic mastocytosis (AdvSM) patients, bezuclastinib shows a 52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID.

EnteroBiotix Completes Enrollment in Phase 2 Trial of EBX-102 for Irritable Bowel Syndrome

EnteroBiotix has finished recruiting 122 patients for its Phase 2 TrIuMPH trial, which investigates EBX-102-02 as a treatment for irritable bowel syndrome (IBS).
The TrIuMPH trial is a randomized, double-blind, placebo-controlled study assessing the safety, tolerability, and efficacy of EBX-102-02 in severe IBS-C and IBS-D patients.

Barinthus Bio's VTP-300 Shows Promise in Phase IIb Trial for Chronic Hepatitis B

Barinthus Bio's Phase IIb HBV003 trial shows that VTP-300, combined with low-dose nivolumab, leads to HBsAg loss in chronic hepatitis B patients.
Eight patients experienced complete HBsAg loss, with two achieving functional cure, defined as sustained HBsAg loss and undetectable HBV DNA off-treatment for six months.

EnteroBiotix Completes Phase 2 Trial Recruitment of EBX-102-02 for Irritable Bowel Syndrome

EnteroBiotix has completed recruitment for its Phase 2 TrIuMPH trial, which is evaluating EBX-102-02 in 122 patients with moderate to severe irritable bowel syndrome (IBS).
The trial includes patients with both constipation-predominant IBS (IBS-C) and diarrhea-predominant IBS (IBS-D), with 62 and 60 participants respectively.

EnteroBiotix Completes Phase 2 Trial Recruitment of EBX-102-02 for Irritable Bowel Syndrome

EnteroBiotix has completed recruitment for its Phase 2 TrIuMPH trial, evaluating EBX-102-02 in 122 patients with severe Irritable Bowel Syndrome (IBS).
The randomized, double-blind, placebo-controlled trial assesses the safety, tolerability, and efficacy of EBX-102-02 over a six-week period.

Ultimovacs' UV1 Fails to Meet Endpoints in Phase II HNSCC Trial

Ultimovacs ASA announced that the Phase II FOCUS trial of UV1 in head and neck squamous cell carcinoma (HNSCC) did not meet its primary or secondary endpoints.
The FOCUS trial evaluated UV1 in combination with pembrolizumab versus pembrolizumab alone in recurrent or metastatic HNSCC patients.

Abivax enrols first participant in Phase IIb Crohn's disease drug trial - MSN

BDTX-1535 Shows Promise in Relapsed/Refractory EGFR-Mutant NSCLC

BDTX-1535, a fourth-generation EGFR TKI, demonstrates encouraging clinical activity in relapsed/refractory EGFR-mutant non-small cell lung cancer (NSCLC).
A phase 2 trial showed a 42% objective response rate (ORR) in patients with osimertinib-resistant EGFR mutations, including C797S.

SAB Biotherapeutics' SAB-142 Shows Promising Safety Profile in Type 1 Diabetes Trial

SAB Biotherapeutics' SAB-142 completes Phase 1 enrollment in healthy volunteers, advancing to enroll patients with type 1 diabetes (T1D).
The Phase 1 trial of SAB-142 demonstrates no serum sickness at the target dose of 2.5mg/kg, a key differentiator from rabbit anti-thymocyte globulin.

Reference News

[1]
Topline results from phase 2b clinical trial of UBX1325 for ...
ground.news · Jan 11, 2025

The ASPIRE phase 2b study is currently in progress, with no bias information available for the sources covering this sto...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy